P is on track to be to market very quickly. People need to remember Brilacidin is a brand new drug, it needs more attention, research and confirmation by the FDA. P is a similar copy of another approved drug which gives it a quicker path to approval. That is why there is a partner standing at the door waiting for the phase 2 data, they know it can be to the market in months!